Crescita Therapeutics Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CAD 17.52 million compared to CAD 23.53 million a year ago. Net loss was CAD 1.99 million compared to net income of CAD 0.862 million a year ago.

Basic loss per share from continuing operations was CAD 0.1 compared to basic earnings per share from continuing operations of CAD 0.04 a year ago. Diluted loss per share from continuing operations was CAD 0.1 compared to diluted earnings per share from continuing operations of CAD 0.04 a year ago.